Diplomat and BioScrip Deals Illustrate Changing Industries

January 1

As independent specialty pharmacies and infusion providers continue to be squeezed by various market pressures, 2019 saw an end to two long-time industry presences. In August, BioScrip, Inc. and Option Care Enterprises, Inc. finalized a merger. And in December, Diplomat Pharmacy, Inc. said that it had agreed to be acquired by UnitedHealth Group unit OptumRx, putting an end to its struggles over the past couple of years.

On Dec. 9, Diplomat and OptumRx unveiled a deal by which OptumRx would acquire Diplomat’s outstanding common stock for $4 per share — well under the $5.81 per share at which it was valued when the markets closed before that weekend. Diplomat’s board unanimously approved the deal, through which OptumRx gains locations in all 50 states and Washington, D.C. The transaction is expected to close early this year.

0
0 Comments

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Another-Immunotherapy-Indication-Will-Be-Withdrawn.jpg
November 16

FDA Grants Interchangeable Status to Humira Biosimilar; Payers Should Prepare Now for 2023 Launches

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image_NSCLC.jpg
November 16

New Tecartus FDA Approval for Adults With ALL Offers Welcome Therapeutic Option

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Specialty-Trend-Increase-Slows-Biosimilars-Are-Having-Impact.jpg
November 16

Prime Therapeutics Launches IntegratedRx – Oncology, Partners on MIP Accreditation

READ MORE
directory-of-health-plans-test-drive-directory-of-health-plans-ad

The Latest

Premium Categories

meet-the-expert-webinar-navigating-the-complex-us-payer-landscape-to-grow-your-business-ad

Meet Our Reporters

Tags

AIS's Directory of Health Plans Annual Election Period/AEP Benefit Design Benefit Management Biosimilars Cell and Gene Therapies Consumer Engagement Court Case COVID Data & Analytics Drug Approvals Drug Pricing Dual Eligibles Employer Group Health Plans Executive Compensation FDA FDA Specialty Approvals Fee-for-service Medicare Financial Results Infographics Infusion Therapy legislation & regulation Managed Medicaid Market access Marketing Medical Costs Medicare Advantage Medicare Advantage Rx Drug Medicare Part D Membership Growth Mergers & Acquisitions News Briefs Oncology Payer Portrait PBMs; Pharmacy Benefit Manager Policy & Politics Premiums Reimbursement Risk Adjustment Site of Care Management Social Determinants of Health Specialty Drugs Stock Performance telehealth Value-based Arrangements

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today